Jamie Samath: With respect to capital allocation, I think our priorities are consistent for how they’ve been for some time now. Our first priority is to invest in the business, both in capital expenditures, which as you’ve seen by our guidance are relatively high to our history this year and in organically investing in operating expenses. Second is to acquire technology externally that gives us differentiated capability or accelerates us in the marketplace. That’s generally license arrangements, IP acquisition or tuck-in acquisitions. And we continue to look at returning cash to shareholders opportunistically. And I think that’s served us well. If you look at kind of the last 18 months, we repurchased 12.6 million shares for $3 billion at an average price of $234. And we did that opportunistically in large part because it reflects kind of the stage of the company. We’re relatively early in the robotics space where we look for growth and I think that served us well.
Robbie Marcus: Great. Thanks a lot.
Operator: Okay. Our next question is from the line of Rick Wise, Stifel. Please go ahead.
Rick Wise: Hi, good afternoon, Gary. Hello everybody. Gary, I recently visited several European hospitals and robotic programs. And frankly, and honestly can’t be more impressed than ever with Intuitive’s European commercial presence and reputation. But I was particularly intrigued to hear one particularly high-volume robotic surgeon talk about what’s next. And he seemed less focused on systems and very much focused on enabling technologies that make everything better, faster, clearer, et cetera. And they included things like integrated CT image overlays during procedures, that aspect of augmented reality tools that bring CT and surgery together. Next juncture in Firefly. He was dreaming of virtual rulers, a dual SureForm 45 and 60 Staplers and haptic feedback.
I mean that was a — it was fascinating to hear. Are these the kinds of innovations that are priorities for you? And are these kind of things you want to make docs like that excited about? Is that what you’re — the kind of stuff you’re working on?
Gary Guthart: You had a long list. I think several of those are important and things that we’ve talked about and have shared with the world. I think the idea of higher confidence ability to identify tissue in real time for the surgeon and we can do that a few different ways. So the Fluorescence Imaging that you described and other advanced imaging technologies that give surgeons the ability to see beyond the surface of the tissue and beyond what you can see with normal white light imaging, we absolutely think that’s helping clinical outcomes and we’re excited about and investing in. Image fusion or data fusion and that’s the CT overlay, the segmentation of preoperative MR and CT scans and the ability to use that in real time during the case, we think can change outcomes and change efficiency in the OR.
Other types of analytic and sensing capabilities we think are really powerful and important. And to the earlier question about AI machine learning machine vision, these things work together. So high-definition images that show you things beyond the surface of the tissue plus Computer Vision plus AI models can give you some predictive analytics that I think are really powerful and would help surgeons get to better outcomes, reduce complications. So I am, like that surgeon, quite excited.
Rick Wise: Great. Just a follow-up, quick follow-up. You — I think if I remember correctly, took a 5% across-the-board price hike on instrumentation. I don’t know if I’m remembering correctly that was to kick in like June 1. Did that happen? Did it help the quarter? And should I assume that it’s going to be a little bit of a offset or a little bit of an instrument tailwind in the second half and beyond? Thank you, Gary.
